Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 154
- Registration Number
- NCT03078556
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: ABC/DTG/3TC immediate release tabletsDrug: ABC/DTG/3TC film-coated dispersible tablets
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 101
- Registration Number
- NCT03016533
- Locations
- 🇿🇼
GSK Investigational Site, Harare, Zimbabwe
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
Phase 3
Active, not recruiting
- Conditions
- HIV InfectionsInfection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 618
- Registration Number
- NCT02951052
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
Phase 3
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- Drug: ABC/DTG/3TC STR - TabletDrug: DTG Tablet
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 631
- Registration Number
- NCT02938520
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 20
- Registration Number
- NCT02893488
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: BMS-663068 (1 tablet at 600 mg)Drug: BMS-663068 (4 tablets at 150 mg each tablet)
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 14
- Registration Number
- NCT02859259
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 722
- Registration Number
- NCT02831764
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 719
- Registration Number
- NCT02831673
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 36
- Registration Number
- NCT02805556
- Locations
- 🇬🇧
GSK Investigational Site, Lisburn, United Kingdom
A Study to Evaluate the Effect of High Fat Meal on Cabotegravir
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT02799264
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath